Long COVID, a debilitating condition following SARS-CoV-2 infection, continues to disable tens of millions of people globally ...

New research showed some long COVID patients get symptom relief by taking an extended course of Paxlovid. Data are ...

UNIGE scientists have developed a groundbreaking technology that creates synthetic molecules mimicking antibodies, potentially revolutionizing disease treatments.

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

The antibody targets a stable part of the bird flu virus, ensuring that the immune protection can resist new variants and offer long-term protection against the globally spreading airborne infection.

It's been five months since the start of the COVID-19 pandemic. Public health experts explain where we are now.

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

The stock is trading at 1.0150, up 0.6573, gaining 183.7573% on volume of over 422 Million shares, with a day's high of $1.11. The stock announced breaking news on its Monoclonal Antibody designed to ...

In total, 5% of dogs and 13% of cats tested positive for COVID-19 on polymerase chain reaction, and 25% and 36%, respectively ...

A prophylactic antibody-based immune therapy protects monkeys against severe disease caused by H5N1 avian flu, University of ...

PITTSBURGH, Jan. 30, 2025 – A prophylactic antibody-based immune therapy protects ... akin to the SARS-CoV-2 mutants that evolved during the COVID-19 pandemic, and provide lasting protection ...